Djeda Belharazem1, Julia Magdeburg2, Ann-Kristin Berton1, Li Beissbarth3, Christian Sauer1, Carsten Sticht4, Alexander Marx1, Ralf Hofheinz5, Stefan Post2, Peter Kienle2, Philipp Ströbel6. 1. Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany. 2. Department of Surgery, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany. 3. Institute of Pathology, University Medical Center Göttingen, Robert-Koch-Str 40, 37075, Göttingen, Germany. 4. Medical Research Center (ZMF), University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany. 5. Medical Clinic, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany. 6. Institute of Pathology, University Medical Center Göttingen, Robert-Koch-Str 40, 37075, Göttingen, Germany. philipp.stroebel@med.uni-goettingen.de.
Abstract
BACKGROUND: Loss of imprinting (LOI) of the insulin-like growth factor 2 (IGF2) is an early event in the development of colorectal cancer (CRC). Whether LOI of IGF2 denotes a molecular or clinical cancer subgroup is currently unknown. METHODS: Tumor biopsies and paired normal mucosa from 399 patients with extensive clinical annotations were analyzed for LOI and IGF2 expression. LOI status in 140 informative cases was correlated with clinicopathologic parameters and outcome. RESULTS: LOI was frequent in normal mucosa and tumors and occurred throughout the large intestine. LOI was unrelated to microsatellite instability, KRAS mutation status, stage, and survival. However, CRC with LOI showed increased IGF2 protein levels and activation of AKT1. Gene expression analysis of tumors with and without LOI and knockdown of IGF2 in cell lines revealed that IGF2 induced distinct sets of activated and repressed genes, including Wnt5a, CEACAM6, IGF2BP3, KPN2A, BRCA2, and CDK1. Inhibition of AKT1 in IGF2-stimulated cells showed that the downstream effects of IGF2 on cell proliferation and gene expression were strictly AKT1-dependent. CONCLUSIONS: LOI of IGF2 is a frequent and early event in CRC that occurs both in the adenomatous polyposis coli (APC) gene-mutated and serrated route of carcinogenesis. LOI leads to overexpression of IGF2, activates IGF1R and AKT1, and is a powerful driver of cell proliferation. Moreover, our results suggest that IGF2 via AKT1 also contributes to non-canonical wnt signaling. Although LOI had no significant impact on major clinical parameters and outcome, its potential as a target for preventive and therapeutic interventions merits further investigation.
BACKGROUND: Loss of imprinting (LOI) of the insulin-like growth factor 2 (IGF2) is an early event in the development of colorectal cancer (CRC). Whether LOI of IGF2 denotes a molecular or clinical cancer subgroup is currently unknown. METHODS: Tumor biopsies and paired normal mucosa from 399 patients with extensive clinical annotations were analyzed for LOI and IGF2 expression. LOI status in 140 informative cases was correlated with clinicopathologic parameters and outcome. RESULTS: LOI was frequent in normal mucosa and tumors and occurred throughout the large intestine. LOI was unrelated to microsatellite instability, KRAS mutation status, stage, and survival. However, CRC with LOI showed increased IGF2 protein levels and activation of AKT1. Gene expression analysis of tumors with and without LOI and knockdown of IGF2 in cell lines revealed that IGF2 induced distinct sets of activated and repressed genes, including Wnt5a, CEACAM6, IGF2BP3, KPN2A, BRCA2, and CDK1. Inhibition of AKT1 in IGF2-stimulated cells showed that the downstream effects of IGF2 on cell proliferation and gene expression were strictly AKT1-dependent. CONCLUSIONS: LOI of IGF2 is a frequent and early event in CRC that occurs both in the adenomatous polyposis coli (APC) gene-mutated and serrated route of carcinogenesis. LOI leads to overexpression of IGF2, activates IGF1R and AKT1, and is a powerful driver of cell proliferation. Moreover, our results suggest that IGF2 via AKT1 also contributes to non-canonical wnt signaling. Although LOI had no significant impact on major clinical parameters and outcome, its potential as a target for preventive and therapeutic interventions merits further investigation.
Authors: Stacey Shiovitz; Monica M Bertagnolli; Lindsay A Renfro; Eunmi Nam; Nathan R Foster; Slavomir Dzieciatkowski; Yanxin Luo; Victoria Valinluck Lao; Raymond J Monnat; Mary J Emond; Nancy Maizels; Donna Niedzwiecki; Richard M Goldberg; Leonard B Saltz; Alan Venook; Robert S Warren; William M Grady Journal: Gastroenterology Date: 2014-05-21 Impact factor: 22.682
Authors: Takashi Sakatani; Atsushi Kaneda; Christine A Iacobuzio-Donahue; Mark G Carter; Sten de Boom Witzel; Hideyuki Okano; Minoru S H Ko; Rolf Ohlsson; Dan L Longo; Andrew P Feinberg Journal: Science Date: 2005-02-24 Impact factor: 47.728
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: S Ogino; M Cantor; T Kawasaki; M Brahmandam; G J Kirkner; D J Weisenberger; M Campan; P W Laird; M Loda; C S Fuchs Journal: Gut Date: 2006-01-11 Impact factor: 23.059
Authors: Marcia Cruz-Correa; Hengmi Cui; Francis M Giardiello; Neil R Powe; Linda Hylind; Angela Robinson; David F Hutcheon; David R Kafonek; Sheri Brandenburg; Yiqian Wu; Xiaobing He; Andrew P Feinberg Journal: Gastroenterology Date: 2004-04 Impact factor: 22.682
Authors: M Elkin; A Shevelev; E Schulze; M Tykocinsky; M Cooper; I Ariel; D Pode; E Kopf; N de Groot; A Hochberg Journal: FEBS Lett Date: 1995-10-23 Impact factor: 4.124
Authors: Yoko Ito; Thibaud Koessler; Ashraf E K Ibrahim; Sushma Rai; Sarah L Vowler; Sayeda Abu-Amero; Ana-Luisa Silva; Ana-Teresa Maia; Joanna E Huddleston; Santiago Uribe-Lewis; Kathryn Woodfine; Maja Jagodic; Raffaella Nativio; Alison Dunning; Gudrun Moore; Elena Klenova; Sheila Bingham; Paul D P Pharoah; James D Brenton; Stephan Beck; Manjinder S Sandhu; Adele Murrell Journal: Hum Mol Genet Date: 2008-06-09 Impact factor: 6.150
Authors: Stefan Küffer; Tobias Gutting; Djeda Belharazem; Christian Sauer; Maurice S Michel; Alexander Marx; Lutz Trojan; Philipp Ströbel Journal: Mol Oncol Date: 2018-01-04 Impact factor: 6.603
Authors: Philip Weidner; Michaela Söhn; Tobias Gutting; Teresa Friedrich; Timo Gaiser; Julia Magdeburg; Peter Kienle; Hermelindis Ruh; Carsten Hopf; Hans-Michael Behrens; Christoph Röcken; Tamar Hanoch; Rony Seger; Matthias P A Ebert; Elke Burgermeister Journal: Oncotarget Date: 2016-08-02